{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:49:08Z","timestamp":1759366148188,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.arteri.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T17:17:12Z","timestamp":1562260632000},"page":"66-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enfermedad cardiovascular progresiva en paciente bajo tratamiento con nilotinib"],"prefix":"10.1016","volume":"32","author":[{"given":"Ricardo","family":"Roa-Chamorro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Torres-Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Garc\u00eda de los R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Puerta-Puerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Gonz\u00e1lez-Bustos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Diego","family":"Mediavilla-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2019.05.002_bib0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2010.01.001","article-title":"The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: a global perspective","volume":"53","author":"Mendis","year":"2010","journal-title":"Prog Cardiovasc Dis."},{"key":"10.1016\/j.arteri.2019.05.002_bib0055","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.arteri.2019.05.002_bib0060","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.arteri.2019.05.002_bib0065","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: Long-term follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.arteri.2019.05.002_bib0095","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.arteri.2019.05.002_bib0100","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.arteri.2019.05.002_bib0080","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.arteri.2019.05.002_bib0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol."},{"key":"10.1016\/j.arteri.2019.05.002_bib0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2018.12.004","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leulemia treated with tyrosine kinase inhibitors","volume":"19","author":"Assun\u00e7ao","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916819300713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916819300713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:31:35Z","timestamp":1759325495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916819300713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0214916819300713"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2019.05.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfermedad cardiovascular progresiva en paciente bajo tratamiento con nilotinib","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}